Kailera Therapeutics Inc. Common Stock (KLRA)
Stock · NASDAQ · Health Care
$16.21as of 8/28/2026
Price chart
Open in TradingViewActive signals
Resistance level
$19.02
Industry
Biotechnology: Pharmaceutical Preparations
About KLRA
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 145
- Website
- www.kailera.com
Fundamentals
- 1-day range
- $16.19$18.26
- Market cap
- $2.24B
- P/E (trailing)
- —
- P/E (forward)
- -3.77
- EPS (trailing)
- $-2.25
- Dividend yield
- —
- Beta
- 2.14
- Avg. volume
- 744.1K
52-week range
$16.19$28.23
Next earnings: October 29, 2026 · EPS estimate $-1.06
Forecasts
5 analyst ratings
Buy 92%
Hold 8%
Sell 0%
1-year price forecast
High
$57
+251.6%
Median
$41
+152.9%
Low
$30
+85.1%
Kailera Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- KLRAKailera Therapeutics Inc. Common Stock$16.26▼ 12.25%Market cap $2.24BP/E —$16.19$28.23
- VERAVera Therapeutics Inc. Class A Common Stock$34.19▼ 1.18%Market cap $2.31BP/E —$21.2$56.05
- NUVBNuvation Bio Inc. Class A Common Stock$6.67▼ 4.65%Market cap $2.14BP/E —$2.87$9.75
- PGENPrecigen Inc. Common Stock$6.94▼ 3.55%Market cap $2.36BP/E —$2.99$7.72
- MLYSMineralys Therapeutics Inc. Common Stock$25.59▼ 1.61%Market cap $2.13BP/E —$14.94$47.65
- NKTRNektar Therapeutics Common Stock$72.57▼ 2.66%Market cap $2.38BP/E —$27.87$109
- RAREUltragenyx Pharmaceutical Inc. Common Stock$25.62▼ 2.46%Market cap $2.46BP/E —$18.29$39.89
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KLRA Kailera Therapeutics Inc. Common Stock | $2.24B | — | $16.26 | ▼ 12.25% | $16.19$28.23 |
| VERA Vera Therapeutics Inc. Class A Common Stock | $2.31B | — | $34.19 | ▼ 1.18% | $21.2$56.05 |
| NUVB Nuvation Bio Inc. Class A Common Stock | $2.14B | — | $6.67 | ▼ 4.65% | $2.87$9.75 |
| PGEN Precigen Inc. Common Stock | $2.36B | — | $6.94 | ▼ 3.55% | $2.99$7.72 |
| MLYS Mineralys Therapeutics Inc. Common Stock | $2.13B | — | $25.59 | ▼ 1.61% | $14.94$47.65 |
| NKTR Nektar Therapeutics Common Stock | $2.38B | — | $72.57 | ▼ 2.66% | $27.87$109 |
| RARE Ultragenyx Pharmaceutical Inc. Common Stock | $2.46B | — | $25.62 | ▼ 2.46% | $18.29$39.89 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- THQ Offers High-Yield Income From Healthcare Stocks (Rating Upgrade)SeekingAlpha · 8/27/2026
- Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) EstimateBenzinga · 8/12/2026
Insider Activity
Insider Actions →Acquired
22.50M
Disposed
15.95M
- Tregoning Kathleen · July 6, 2026 · Grant175.0K
- Ronald C. Renaud Jr. · June 9, 2026 · Option Exercise38.1K @ $5.25
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. · April 20, 2026 · Conversion708.8K
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. · April 20, 2026 · Conversion4.97M
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. · April 20, 2026 · Conversion2.03M
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. · April 20, 2026 · Conversion9.48M
- RTW INVESTMENTS, LP · April 20, 2026 · Conversion2.03M
- RTW INVESTMENTS, LP · April 20, 2026 · Conversion8.25M
- RTW INVESTMENTS, LP · April 20, 2026 · Buy500.0K @ $16
- RTW INVESTMENTS, LP · April 20, 2026 · Conversion10.28M
See the full, filterable feed with live charts on the MarketWall dashboard.